Whisky and Spirits

What it is

Whisky, vodka, gin, rum and brandy are distilled drinks, usually around 40% alcohol by volume and served in small measures. Their health effects come almost entirely from ethanol; clear spirits like vodka contain essentially nothing else, while barrel-aged spirits such as whisky, cognac and armagnac pick up oak compounds that have been tested for extra effects in small trials [1]. The International Agency for Research on Cancer classifies ethanol as a Group 1 carcinogen [2].

How it might work

Alcohol is proposed to raise 'good' HDL cholesterol and apolipoprotein A1, to boost adiponectin, and to speed the first steps of reverse cholesterol transport, the process that moves cholesterol out of tissues [3] [4]. For gallstones, researchers propose less cholesterol-saturated bile, higher HDL and stronger gallbladder contractions [5]. Non-alcohol compounds in aged spirits may matter too: in a small trial, armagnac inhibited platelet clumping more than the same amount of vodka, which the authors credited to its non-alcoholic fraction rather than the alcohol [1]. These are proposed mechanisms, not proof of benefit in people.

What the research says

Heart-risk blood markers. In a meta-analysis of 44 interventional studies, alcohol raised HDL ('good') cholesterol by 0.094 mmol/L and apolipoprotein A1, raised adiponectin and lowered fibrinogen — changes that looked favourable, and were similar for wine, beer and spirits [3]. Whisky itself was tested: 40 g of alcohol a day as four glasses of whisky for 17 days raised adiponectin by 11% in 23 middle-aged men [6] and raised the capacity of blood serum to move cholesterol out of cells by 17.5% [4]. In 11 men, red wine, beer and Dutch gin all raised cholesterol-efflux capacity by 6.2% and increased cholesterol esterification by 10.8%, with the significant changes after beer and spirits [7]. Vodka (3 units a day for 2 weeks) raised apolipoprotein A1 — but not adiponectin — in 77 healthy men [8]. These are markers, not heart attacks: when trials measured coronary blood flow directly, 1–2 weeks of vodka, white wine or red wine changed nothing [9], and cognac did not change coronary flow reserve [10].

Type 2 diabetes. A 2023 analysis of 55 cohort studies (2.65 million people) found women who drank around 16 g of alcohol a day had 31% lower type 2 diabetes risk than lifetime abstainers, with no benefit above 49 g a day, and no significant link in men [11]. An earlier meta-analysis of 706,716 people found light and moderate drinkers had 17% and 26% lower risk than the lowest-intake group [12], while in Asian men drinking up to 57 g a day showed no benefit and heavier intake raised risk [13]. The type of drink matters: wine was linked to a 15% lower risk, beer 4% and spirits 5%, with the spirits peak at just 7–15 g a day [14].

Gallstones. A 2019 meta-analysis (16 case-control and 8 cohort studies) found drinkers had 16% lower odds of gallstone disease than non-drinkers; light drinkers were 4% lower and moderate drinkers 20% lower [5]. A 2017 meta-analysis found the highest intake group had 38% lower risk than the lowest — about 12% lower for every extra 10 g of alcohol a day [15]. The picture has since muddied: a 2025 review of 139 studies found no significant link between alcohol and gallstone prevalence [16], and among people with silent gallstones being watched, drinkers were more likely to develop symptoms (RR 1.32) [17].

Frailty. One 2024 meta-analysis of 9 cohort studies found a slightly lower frailty risk up to about 20 g a day, but rated the evidence low quality, with most studies at serious risk of bias [18].

Not all drinks behave alike. In UK Biobank, people who drank mostly spirits had higher mortality, heart and liver risks than red-wine drinkers of similar intake [19]; in a different UK Biobank analysis, spirits intake was linked with higher all-cause mortality, cardiovascular events and cancer [20]. In 187,294 Norwegians, low wine drinking was linked to lower death rates, while combinations of beer and spirits without wine showed no protection [21]. A meta-analysis of 10 studies found no J-shaped relationship between spirits and vascular risk, though wine and beer showed one [22]. At low-to-moderate levels, reviews comparing beverages overall find the differences inconsistent [23].

Doses used in studies

Whisky trials gave 40 g of alcohol a day as four glasses with dinner for 17 days [6] [4]; another spirits trial gave 40 g a day for 3 weeks [7]. Vodka was tested at 3 units a day for 2 weeks [8], and armagnac or vodka at 30 ml a day for 2 weeks [1]. In the diabetes analysis, the peak benefit was around 16 g a day [11]; in the beverage-specific analysis, spirits peaked at 7–15 g a day [14]. The gallstone meta-analysis grouped intake into light, moderate and high bands based on each study's own categories [5].

Safety and interactions

• Cancer: ethanol is a Group 1 carcinogen, and across 139 cohort studies even light drinking was linked to higher oesophageal, colorectal and breast cancer risk; no amount has been shown to be safe for cancer risk [24] [2].
• Blood pressure: in 104,467 adults, blood pressure rose with every weekly drink, similarly for spirits, beer and wine [25].
• Higher intake: from 45 g of alcohol a day, all-cause mortality risk rises, with risk starting at lower amounts for women [26]; heavy drinking is also linked to haemorrhagic stroke [27].
• Pregnancy and breastfeeding: alcohol in pregnancy causes fetal alcohol spectrum disorder, which affects about 7.7 in 1,000 children worldwide; no safe amount has been established [28].
• Medicines: most antibiotic warnings about alcohol rest on weak evidence, but some drugs (for example certain cephalosporins, ketoconazole and griseofulvin) can cause a disulfiram-like reaction, and erythromycin may work less well [29]; spirit-heavy drinking was linked to higher cirrhosis rates than wine drinking in UK Biobank [19].
• Who should ask a doctor first: people with liver disease, uncontrolled blood pressure, a history of alcohol problems, or who take medicines that interact with alcohol.

Caveats and open questions

Most spirit-specific evidence comes from small, short trials measuring blood markers rather than disease outcomes [6] [4] [8]. Cohort comparisons cannot separate the drink from the drinker: the higher risks seen in spirit drinkers may reflect smoking, diet or drinking patterns rather than the spirit itself [19]. The gallstone dose-response relied on case-control studies, and the authors detected publication bias and cautioned against drinking for gallstone prevention [5]. Beverages come out broadly similar in reviews, with wine ahead in some cohorts [23] [21]. Whether moderate drinking helps anyone remains contested — genetic studies find no heart protection [30].